Insulet Corporation Stock News

Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Resear...

Insulet (PODD 9.87%), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperformance: GAAP revenue rose to $649.1 million, beating estimates by nearly $35 million, while Adjusted earnings per share (EPS) (non-GAAP) topped analyst forecasts by $0.25.

Insulet stock surged Thursday after the insulin pump-maker walloped second-quarter forecasts and raised its sales guidance for the year.

Medical device maker Insulet beat Wall Street estimates for second-quarter profit and revenue on strong demand for its wearable insulin pumps, sending its shares up nearly 10% in premarket trading on Thursday.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Compa...

Growth stocks can be expensive, but if you are trying to be aggressive with a portion of your investment portfolio, you often have to pay a premium for the privilege.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call...

Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.